Metalloproteinase and stroke infarct size: role for anti‐inflammatory treatment?

Deregulation of matrix metalloproteinases (MMPs), the largest class of human proteases, has been implicated in brain damage in both animal and human studies. Some MMPs are elevated after stroke (both in plasma and in brain tissue), and their expression is enhanced by t‐PA during thrombolysis related to hemorrhagic transformation events. Although the exact cellular source of MMPs remains unknown, brain endothelium, astrocytes, neurons, and inflammatory‐activated cells, such as neutrophils, may release MMP‐2, MMP‐3, MMP‐8, MMP‐9, MMP‐10, and/or MMP‐13. Neurovascular perturbations occurring after stroke lead to blood–brain barrier leakage, edema, hemorrhage, leukocyte infiltration, and progressive inflammatory reactions to brain injury over hours or even days after the initial stroke. Synthesized MMP inhibitors and several compounds used for stroke secondary prevention, such as anti‐inflammatory drugs, might decrease MMPs and improve the acute treatment of human brain ischemia without compromising the beneficial effects of matrix plasticity during stroke recovery.

[1]  G. Bernardi,et al.  Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. , 2007, International review of neurobiology.

[2]  C. Molina,et al.  Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. , 2003, Journal of neurosurgery.

[3]  Xinyu Zhao,et al.  Endogenous Matrix Metalloproteinase (MMP)‐3 and MMP‐9 Promote the Differentiation and Migration of Adult Neural Progenitor Cells in Response to Chemokines , 2008, Stem cells.

[4]  Kamin J. Johnson,et al.  Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. , 2001, Nature Medicine.

[5]  À. Rovira,et al.  A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke , 2005, Stroke.

[6]  E. Lo,et al.  Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke , 2006, Stroke.

[7]  H. Lijnen,et al.  Stromelysin‐1 (MMP‐3) is critical for intracranial bleeding after t‐PA treatment of stroke in mice , 2007, Journal of thrombosis and haemostasis : JTH.

[8]  Gary A. Rosenberg,et al.  Proteolytic Cascade Enzymes Increase in Focal Cerebral Ischemia in Rat , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  C. Ali,et al.  Neuroprotection and stroke: time for a compromise , 2007, Journal of neurochemistry.

[10]  H. H. Marti,et al.  Matrix Metalloproteinase-9 Mediates Hypoxia-Induced Vascular Leakage in the Brain via Tight Junction Rearrangement , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  V. Demarin,et al.  Matrix metalloproteinases and their inhibitors in different acute stroke subtypes , 2006, Clinical chemistry and laboratory medicine.

[12]  J. Koziol,et al.  Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral Ischemia , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  F. Barone,et al.  Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. , 1998, Stroke.

[14]  Jeffrey F. Thompson,et al.  Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  S. Taheri,et al.  Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-α in the Rat , 2007, Journal of Pharmacology and Experimental Therapeutics.

[16]  G. Rosenberg,et al.  Matrix Metalloproteinases in Cerebrovascular Disease , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  S. Taheri,et al.  Early Beneficial Effect of Matrix Metalloproteinase Inhibition on Blood—Brain Barrier Permeability as Measured by Magnetic Resonance Imaging Countered by Impaired Long-Term Recovery after Stroke in Rat Brain , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  W. Dietrich,et al.  Inflammatory Mechanisms after Ischemia and Stroke , 2003, Journal of neuropathology and experimental neurology.

[19]  J. Koziol,et al.  Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. , 2003, Stroke.

[20]  G. Rosenberg,et al.  Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation , 2006, Neurobiology of Disease.

[21]  Jiankun Cui,et al.  S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death , 2002, Science.

[22]  A. Clark,et al.  Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia , 1997, Neuroscience Letters.

[23]  G. Rosenberg,et al.  Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. , 1998, Stroke.

[24]  E. Lo,et al.  Role of Matrix Metalloproteinases in Delayed Neuronal Damage after Transient Global Cerebral Ischemia , 2004, The Journal of Neuroscience.

[25]  D. Burggraf,et al.  Microvascular Basal Lamina Injury after Experimental Focal Cerebral Ischemia and Reperfusion in the Rat , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[27]  J. Montaner,et al.  Tissue plasminogen activator (t‐PA) promotes neutrophil degranulation and MMP‐9 release , 2008, Journal of leukocyte biology.

[28]  S. Takai,et al.  Trandolapril reduces infarction area after middle cerebral artery occlusion in rats. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[29]  E. Candelario-Jalil,et al.  Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia , 2009, Neuroscience.

[30]  V. Perry,et al.  Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke , 1997, Neuropathology and applied neurobiology.

[31]  A. Nishiyama,et al.  The expression of matrix metalloproteinase-13 is increased in vessels with blood–brain barrier impairment in a stroke-prone hypertensive model , 2009, Hypertension Research.

[32]  E. Lo,et al.  Extracellular proteolysis in brain injury and inflammation: Role for plasminogen activators and matrix metalloproteinases , 2002, Journal of neuroscience research.

[33]  Á. Chamorro,et al.  Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke , 2009, Journal of Neurology.

[34]  Á. Chamorro,et al.  Activation of Matrix Metalloproteinase‐3 and Agrin Cleavage in Cerebral Ischemia/Reperfusion , 2004, Journal of neuropathology and experimental neurology.

[35]  L. Kotra,et al.  Matrix metalloproteinases: structures, evolution, and diversification , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  J. Arenillas,et al.  Matrix Metalloproteinase Expression After Human Cardioembolic Stroke: Temporal Profile and Relation to Neurological Impairment , 2001, Stroke.

[37]  D. Krieger,et al.  Mild to Moderate Hypothermia Prevents Microvascular Basal Lamina Antigen Loss in Experimental Focal Cerebral Ischemia , 2004, Stroke.

[38]  H. Lijnen.  Plasmin and Matrix Metalloproteinases in Vascular Remodeling , 2001, Thrombosis and Haemostasis.

[39]  J. Serena,et al.  Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke , 2003, Stroke.

[40]  Z. Stelmasiak,et al.  Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. , 2006, Folia biologica.

[41]  S. Takai,et al.  Inhibition of Matrix Metalloproteinase-9 Activity by Trandolapril after Middle Cerebral Artery Occlusion in Rats , 2007, Hypertension Research.

[42]  C. Libert,et al.  Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation , 2007, Journal of leukocyte biology.

[43]  M. Fini,et al.  Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia , 2001, The Journal of Neuroscience.

[44]  K. Chergui,et al.  Many ways to Rome — multiple approaches to novel drugs , 2007 .

[45]  M. Moskowitz,et al.  tPA and proteolysis in the neurovascular unit. , 2004, Stroke.

[46]  Á. Chamorro,et al.  Neutrophil Infiltration Increases Matrix Metalloproteinase-9 in the Ischemic Brain after Occlusion/Reperfusion of the Middle Cerebral Artery in Rats , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  L. Matrisian,et al.  Matrix Metalloproteinases as Mediators of Reproductive Function , 2022 .

[48]  K. Rhodes,et al.  Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke , 2008, Stroke.

[49]  K. Arai,et al.  Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator , 2003, Nature Medicine.

[50]  J. Montaner,et al.  Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. , 2009, Journal of proteome research.

[51]  B. Rosen,et al.  Role of matrix metalloproteinases in delayed cortical responses after stroke , 2006, Nature Medicine.

[52]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[53]  E. Lo,et al.  Extracellular proteolytic pathophysiology in the neurovascular unit after stroke , 2004, Neurological research.

[54]  J. Michel.  Anoikis in the cardiovascular system: known and unknown extracellular mediators. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[55]  S. Heiland,et al.  Diphenyleneiodonium and dimethylsulfoxide for treatment of reperfusion injury in cerebral ischemia of the rat , 2007, Brain Research.

[56]  P. Soccal,et al.  Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. , 2006, Frontiers in bioscience : a journal and virtual library.

[57]  E. Tremoli,et al.  Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. , 2005, Neurotoxicology.

[58]  G. Rosenberg,et al.  Closure of the Blood-Brain Barrier by Matrix Metalloproteinase Inhibition Reduces rtPA-Mediated Mortality in Cerebral Ischemia With Delayed Reperfusion , 2003, Stroke.

[59]  G. Opdenakker,et al.  Matrix Metalloproteinase-9 Facilitates Remyelination in Part by Processing the Inhibitory NG2 Proteoglycan , 2003, The Journal of Neuroscience.

[60]  J. Montaner,et al.  Matrix Metalloproteinase-13 is Activated and is found in the Nucleus of Neural Cells after Cerebral Ischemia , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[62]  R. Colello,et al.  Traumatic brain injury induced cell proliferation in the adult mammalian central nervous system. , 2002, Journal of neurotrauma.

[63]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[64]  O. Lindvall,et al.  Neuronal replacement from endogenous precursors in the adult brain after stroke , 2002, Nature Medicine.

[65]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[66]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Neuroblast Cell Migration from the Subventricular Zone after Stroke , 2006, The Journal of Neuroscience.

[67]  M. Fujimura,et al.  Overexpression of Copper and Zinc Superoxide Dismutase in Transgenic Mice Prevents the Induction and Activation of Matrix Metalloproteinases after Cold Injury-Induced Brain Trauma , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[68]  S. Carmichael,et al.  A Critical Role of Erythropoietin Receptor in Neurogenesis and Post-Stroke Recovery , 2006, The Journal of Neuroscience.

[69]  M. Fini,et al.  Role for Matrix Metalloproteinase 9 after Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[70]  Chun-Hua Wang,et al.  5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9 , 2009, Neurological research.

[71]  R. Kauppinen,et al.  Minocycline Protects against Permanent Cerebral Ischemia in Wild Type but Not in Matrix Metalloprotease-9-Deficient Mice , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  Alex Rovira,et al.  Plasmatic Level of Neuroinflammatory Markers Predict the Extent of Diffusion-Weighted Image Lesions in Hyperacute Stroke , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[73]  D. Atochin,et al.  Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia , 2005, Stroke.

[74]  K. Liu,et al.  Normobaric hyperoxia attenuates early blood–brain barrier disruption by inhibiting MMP‐9‐mediated occludin degradation in focal cerebral ischemia , 2009, Journal of neurochemistry.

[75]  P. Lapchak,et al.  Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke , 2000, Stroke.

[76]  Jiankun Cui,et al.  A Highly Specific Inhibitor of Matrix Metalloproteinase-9 Rescues Laminin from Proteolysis and Neurons from Apoptosis in Transient Focal Cerebral Ischemia , 2005, The Journal of Neuroscience.

[77]  J. Arenillas,et al.  Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage: Relationship to Clinical and Radiological Outcome , 2004, Stroke.

[78]  S. Itohara,et al.  Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia , 2001, Neuroreport.

[79]  E. Lo,et al.  MMP-9–Positive Neutrophil Infiltration Is Associated to Blood–Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke , 2008, Stroke.

[80]  D. Hess,et al.  Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke , 2006, BMC Neuroscience.

[81]  K. Furie,et al.  Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke , 2006, Neurology.

[82]  A. Mazar,et al.  Activation Systems for Latent Matrix Metalloproteinase-2 are Upregulated Immediately after Focal Cerebral Ischemia , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[83]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[84]  E. Lo,et al.  Multiphasic roles for matrix metalloproteinases after stroke. , 2008, Current opinion in pharmacology.

[85]  J. Arenillas,et al.  Matrix Metalloproteinase Expression Is Related to Hemorrhagic Transformation After Cardioembolic Stroke , 2001, Stroke.

[86]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[87]  S. Nam,et al.  Inhibition of matrix metalloproteinase-9 attenuated neural progenitor cell migration after photothrombotic ischemia , 2008, Brain Research.

[88]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[89]  Eng H. Lo,et al.  Neurological diseases: Mechanisms, challenges and opportunities in stroke , 2003, Nature Reviews Neuroscience.

[90]  E. Lo,et al.  Reduction of Tissue Plasminogen Activator-Induced Matrix Metalloproteinase-9 by Simvastatin in Astrocytes , 2006, Stroke.

[91]  Shu-Wei Sun,et al.  Dynamic Changes in Cerebral Blood Flow and Angiogenesis After Transient Focal Cerebral Ischemia in Rats: Evaluation With Serial Magnetic Resonance Imaging , 2002, Stroke.

[92]  J. Koziol,et al.  MMP-2 and MMP-9 levels in peripheral blood after subarachnoid hemorrhage , 2006, Journal of the Neurological Sciences.

[93]  P. Bracci,et al.  Matrix Metalloproteinase-9 and Myeloperoxidase Expression: Quantitative Analysis by Antigen Immunohistochemistry in a Model of Transient Focal Cerebral Ischemia , 2004, Stroke.

[94]  S. Moochhala,et al.  Involvement of ROS in BBB dysfunction , 2009, Free radical research.